biostudies-literatureUnknown46(5)Dizdarevic SBayer<h4>Purpose</h4>REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy.<h4>Methods</h4>Radium-223 was administered in routine clinical practice. Interim safety analysis was planned after enrolment of the first 600 patients. Patient characteristics and safety data by previous administration of chemotherapy (docetaxel and/or cabazitaxel) were investigated.<h4>Results</h4>This interim analysis included 583 patients. Median duration of observation was 7 months (range, 0-20). Nineteen patients treated with concomitant chemotherapy were excluded, 564 (97%) were eligible for exploratory analysiEuropean journal of nuclear medicine and molecular imaging1102-1110https://www.ebi.ac.uk/biostudies/studies/S-EPMC6451709biostudies-literatureInterim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.PMC6451709Bourre JCEzziddin SKalinovsky JPetersen PMDizdarevic Sla Fougere CBayh IVersari ADu YValdagni REssler MPaganelli GfalseInterim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.<h4>Purpose</h4>REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy.<h4>Methods</h4>Radium-223 was administered in routine clinical practice. Interim safety analysis was planned after enrolment of the first 600 patients. Patient characteristics and safety data by previous administration of chemotherapy (docetaxel and/or cabazitaxel) were investigated.<h4>Results</h4>This interim analysis included 583 patients. Median duration of observation was 7 months (range, 0-20). Nineteen patients treated with concomitant chemotherapy were excluded, 564 (97%) were eligible for exploratory analysi2019-01-01T00:00:00Z2019 May2026-04-30T01:36:56.2Z2019-06-06T21:07:14ZS-EPMC64517093063750110.1007/s00259-019-4261-y